A drug use prepared by compound for reducing side effects produced by camptothecin is provided. The compound is selected from nicotinamide, compound C, and pharmaceutically-acceptable agents such as carrier agent, excipient, diluent, auxiliary agent, and the like. A method using in-vitro biomarker for screening drug is also provided, which is capable of detecting dephosphorylation degree of the biomarker after administration. If the dephosphorylation degree of the biomarker is negatively correlated to the protein FoxO1 dephosphorylation degree after adminstration or the protein ATGL expression quantity after adminstration, this drug is qualified.本發明係關於一種使用化合物製備用於減少喜樹鹼(camptothecin)所產生副作用之藥物的用途,其中該化合物係選自菸鹼醯胺(nicotinamide)、化合物C(compound C),及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等;本發明另提供一種利用活體外生物標記作為篩選藥物的方法,偵測給藥後該生物標記去磷酸化程度,若與給藥後的蛋白質FoxO1去磷酸化程度或蛋白質ATGL的表達量成負相關,則為合適的藥物。
